Active surveillance: Pitfalls to consider

Archivos Espanoles de Urologia

Volumn 64, Issue 8, 2011, Pages 695-702

  Ercole, Barbara ^a   Parekh, Dipen J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Active Surveillance; Prostate cancer; Prostate neoplasm; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; BIBLIOGRAPHIC DATABASE; BLOOD; CANCER GRADING; DIAGNOSTIC ERROR; DISEASE COURSE; HEALTH SURVEY; HUMAN; LABORATORY DIAGNOSIS; MALE; NEEDLE BIOPSY; PATHOLOGY; PROSTATE TUMOR; REVIEW; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNNECESSARY PROCEDURE; UTILIZATION REVIEW;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; DATABASES, BIBLIOGRAPHIC; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; FALSE POSITIVE REACTIONS; HUMANS; MALE; NEOPLASM GRADING; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 80055007731     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA: a Cancer Journal for Clinicians. 2010; 60:277-300.
2. Welch HG, Albertsen PC. Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005. J Natl Cancer Inst. 2009;101:1-5.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1;22(11):2141-9. (Pubitemid 41095147)
4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama. 2005 May 4;293(17):2095-101. (Pubitemid 40617061)
5. Weissbach L, Altwein J. Active surveillance or active treatment in localized prostate cancer? Dtsch Arztebl Int. 2009 May;106(22):371-6.
6. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008 Jan;53(1):68-80. (Pubitemid 350166735)
7. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun;177(6):2106-31. (Pubitemid 46726449)
8. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009 Jun;55(6):1321-30.
9. Parekh DJ. Active Surveillance - Beware of the Risks J Urol. 2009 December;in print.
10. Johansson J-E, Andren O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. Jama. 2004 Jun 9;291(22):2713-9. (Pubitemid 38725420)
11. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003 Jun 18;95(12):868-78. (Pubitemid 36833878)
12. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of Localized Prostate Cancer Following Conservative Management. Jama. 2009;302(11):1202-9.
13. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck DP, Chen M-H. Cancer-Specific Mortality Afer Surgery or Radiation for Patients with Clinically Localized Prostate Cancer Managed During the Prostae-Specific Antigen Era. J Clin Oncol. [Journal Article]. 2003 June 1, 2003;21(11):2163-72. (Pubitemid 46606365)
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8. (Pubitemid 34017254)
15. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov;170(5):1792-7. (Pubitemid 37254930)
16. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007 Jan;177(1):107-12; discussion 12. (Pubitemid 44879468)
17. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schroder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer. 2007 Nov 15;110(10):2218-21. (Pubitemid 350100743)
18. Stapleton AMF, Pinnock CB. Nomograms for prostate cancer-is their use evidence-based?. Nat Clin Pract Urol. 2005 Oct;2(10):462-3. (Pubitemid 41594395)
19. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008 Aug;54(2):274-90.
20. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15;112(8):1650-9. (Pubitemid 351536825)
21. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007 May;51(5):1244-50; discussion 51.
22. el-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int. 2004 Mar;93(4):510-5.
23. Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, et al. Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen. Oncology. 2004;67(3-4):194-202. (Pubitemid 39551701)
24. Miyamoto RK, Thompson IM. The Reliability of Digital Rectal Exam, PSA, Repeat Prostate Biospy and Endorectal MRI for Following Patients with Clinically Localized Prostate Cancer on Active Surveillance. J Urol. 2008;179(Supplement 1):154.
25. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 2005 Aug;66(2):356-60. (Pubitemid 41138097)
26. Mariappan P, Chong WL, Sundram M, Mohamed SR. Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. BJU Int. 2004 Aug;94(3):307-10. (Pubitemid 39120169)
27. Mian BM, Lehr DJ, Moore CK, Fisher HA, Kaufman RP, Jr., Ross JS, et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology. 2006 Feb;67(2):379-83. (Pubitemid 43189860)
28. Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, et al. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology. 2009 May;73(5):1087-91.
29. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002 Mar;167(3):1231-4. (Pubitemid 34132060)
30. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004 Apr;171(4):1520-4. (Pubitemid 38365409)
31. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol. 2006 Oct;176(4 Pt 1):1392-7; discussion 7-8.
32. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007 Apr 4;99(7):526-32. (Pubitemid 47073555)
33. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 1998 Jan 15;82(2):342-8. (Pubitemid 28060252)
34. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003 Nov 1;21(21):4001-8. (Pubitemid 46606215)
35. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008 Dec;54(6):1297-305.
36. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004 Jul 8;351(2):125-35.
37. D'Amico AV, Chen M-H. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.[comment]. J Clin Oncol. 2009 Aug 1;27(22):3575-6.
38. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008 Mar;53(3):468-77. (Pubitemid 351179007)
39. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002 Apr;167(4):1664-9. (Pubitemid 34240696)
40. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2000 Jul;164(1):81-8. (Pubitemid 30434265)
41. Thong AE. A Single Microfocus (5% or Less) of Gleason 6 Prostate Cancer at Biopsy-Can We Predict Adverse Pathological Outcomes? J Urol. 2008;180(6):2436-40.
42. Griffin CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol. 2007 Sep;178(3 Pt 1):860-3; discussion 3. (Pubitemid 47224947)
43. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Jr., Terris MK, et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr;175(4):1298-302; discussion 302-3.
44. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006 Mar 1;98(5):355-7. (Pubitemid 43338215)
45. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007 Dec;178(6):2359-64; discussion 64-5.
46. Khatami A, Damber JE, Lodding P, Pihl CG, Hugosson J. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?-A case control study. Scand J Urol Nephrol. 2003;37(3):213-7. (Pubitemid 36791819)
47. Thong MS, Mols F, Kil PJ, Korfage IJ, van de Poll-Franse LV. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 2009 Aug 28.
48. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schroder FH, Bangma CH, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009 Sep 1;115(17):3868-78.
49. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007 Sep;100(3):540-3. (Pubitemid 47205468)
50. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54.
51. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson S-O, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005 May 12;352(19):1977-84. (Pubitemid 40638368)
52. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005 May;95(7):956-60. (Pubitemid 40655686)
53. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007 Dec;52(6):1560-3. (Pubitemid 350052404)
54. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009 Jan;30(1):81-7.
55. Donovan, Hamdy F, Neal D, Peters T, Oliver S. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1-88.